Daniel Cho covers the business and financial dimensions of biotechnology and healthcare, with an emphasis on how investment trends reflect deeper shifts in innovation and risk. His reporting explores capital allocation, strategic deals, and market signals across the life sciences. At The Catalyst Brief, Daniel connects financial activity to scientific progress and policy developments to provide a more complete view of the industry.
148 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Biotech InnovationEli Lilly’s $2.8 billion upfront acquisition of AtaiBeckley highlights mainstream industry interest in psychedelic-based therapies for mental illness. This move significantly broadens Lilly's neuroscience portfolio and signals potential shifts in how major pharmaceutical companies approach mental health treatment innovation.
Daniel ChoJul 16, 2026
Regulatory & PolicyThe Coalition Against Surprise Medical Billing has launched a campaign against new legislative efforts to enforce the No Surprises Act. Critics contend the enforcement bill could exacerbate existing problems with the IDR system, while policymakers argue for stronger patient protections.
Daniel ChoJul 15, 2026
Biopharmaceutical IndustryThe recent workforce reductions at EMD Serono mark yet another sign of evolving economic pressures in the research-driven pharmaceutical industry. This development, closely tracked by industry watchers, highlights ongoing restructuring efforts and their multifaceted consequences across pharma pipelines, workforce stability, and long-term innovation.
Daniel ChoJul 13, 2026
Regulatory & PolicyThe strength of the FDA’s rare disease decisions depends in part on whether patient communities have a meaningful seat at the table during advisory committee meetings. As the drug development landscape evolves, the agency faces renewed calls for a patient-first vision that more formally integrates lived experience into regulatory assessment and approval.
Daniel ChoJul 13, 2026
Biotech InnovationThe scientific community continues to make strides in understanding and treating Alzheimer’s disease. At AAIC 2026, tau protein research and blood-brain barrier breakthroughs are at the forefront, potentially reframing future therapeutic pathways. This in-depth analysis contextualizes the significance of these scientific advancements.
Daniel ChoJul 13, 2026
Healthcare InvestmentWith fresh capital, Handspring aims to deliver scalable solutions for children’s mental health, matching patients to the right level of care and avoiding unnecessary overuse of intensive, expensive options. This funding round marks a significant step forward in addressing mismatches in mental health care and expanding access nationwide.
Daniel ChoJul 11, 2026
Regulatory & PolicyIn a low-profile move, the Food and Drug Administration (FDA) has pushed back the deadline to implement its ban on electric shock devices utilized to manage self-injurious and aggressive behaviors. This delay—occurring amid heightened tensions between regulatory oversight and patient rights—highlights broader challenges facing U.S. regulatory practice and behavioral healthcare.
Daniel ChoJul 10, 2026
Regulatory & PolicyThe Affordable Care Act (ACA) marketplace is facing intensified pressures as insurers propose another round of double-digit premium increases. This pattern, echoing last year’s trends, is attributed to rising healthcare costs and shifting federal policy. Coupled with declining enrollment, the developments may have sweeping implications for policyholders, payers, and policymakers.
Daniel ChoJul 9, 2026
Biotech InnovationIn the wake of FDA’s policy evolution away from exclusive reliance on animal testing, startups and established companies alike are racing to refine preclinical drug testing methods. While technologies like organoids and organ-on-a-chip platforms are gaining popularity, a new push for whole-organ testing by a Connecticut-based startup may reshape industry standards for evaluating human drug response.
Daniel ChoJul 9, 2026
AI in Drug DiscoveryWhile AI promises to revolutionize many aspects of healthcare, mental health professionals argue that certain skills—such as navigating patient discomfort, challenging assumptions, and asking deeper questions—remain uniquely human. Bridging the gap between technology and compassionate care is increasingly seen as essential in the evolving mental health landscape.
Daniel ChoJul 5, 2026
Biotech InnovationRoche is advancing its next-generation KRAS G12C inhibitor, divarasib, after Phase 3 data suggest it may offer greater potency and selectivity than current market options from Amgen and Bristol Myers Squibb. This announcement highlights an increasingly competitive race to address one of lung cancer’s most challenging genetic mutations and could mark a pivotal shift in standards of care for patients whose cancers are driven by KRAS G12C mutations.
Daniel ChoJul 3, 2026
Medical TechnologyAs cyberwarfare tactics escalate globally, U.S. hospital networks are now recognized targets—often with limited capacity to withstand or recover from attacks. Experts warn that ideological, political, and financial motivations drive a complex threat landscape, with vulnerabilities spanning legacy systems, critical infrastructure, and institutional readiness.
Daniel ChoJul 3, 2026